TriSalus Life Sciences, Inc.
TLSI
$5.34
-$0.16-2.91%
NASDAQ
| 03/31/2025 | 12/31/2024 | 09/30/2024 | 06/30/2024 | 03/31/2024 | |
|---|---|---|---|---|---|
| Net Income | -27.20M | -30.03M | -55.56M | -54.66M | -64.30M |
| Total Depreciation and Amortization | 728.00K | 731.00K | 732.00K | 719.00K | 675.00K |
| Total Amortization of Deferred Charges | 847.00K | 612.00K | 434.00K | 267.00K | -- |
| Total Other Non-Cash Items | -1.38M | -2.61M | 16.20M | 6.14M | 11.95M |
| Change in Net Operating Assets | -7.47M | -9.55M | -6.11M | -7.60M | 737.00K |
| Cash from Operations | -34.48M | -40.84M | -44.31M | -55.13M | -50.94M |
| Capital Expenditure | -1.03M | -345.00K | -667.00K | -676.00K | -647.00K |
| Sale of Property, Plant, and Equipment | 40.00K | -- | -- | -- | -- |
| Cash Acquisitions | -- | -- | -1.00M | -1.00M | -1.00M |
| Divestitures | -- | -- | -- | -- | -- |
| Other Investing Activities | -- | -- | 1.00M | 66.00K | 67.00K |
| Cash from Investing | -993.00K | -345.00K | -667.00K | -1.61M | -1.58M |
| Total Debt Issued | 35.00M | 25.00M | 25.00M | 25.00M | -- |
| Total Debt Repaid | -133.00K | -84.00K | -87.00K | -87.00K | -87.00K |
| Issuance of Common Stock | 12.74M | 15.61M | 12.69M | 6.87M | 3.28M |
| Repurchase of Common Stock | -- | -- | -- | -- | -- |
| Issuance of Preferred Stock | -- | -- | 0.00 | 4.51M | 10.92M |
| Repurchase of Preferred Stock | -- | -- | -- | -- | -- |
| Total Dividends Paid | -- | -- | -- | -- | -- |
| Other Financing Activities | -3.11M | -2.59M | -2.61M | 33.13M | 35.72M |
| Cash from Financing | 44.50M | 37.94M | 34.99M | 69.42M | 49.83M |
| Foreign Exchange rate Adjustments | -- | -- | -- | -- | -- |
| Miscellaneous Cash Flow Adjustments | -- | -- | -- | -- | -- |
| Net Change in Cash | 9.03M | -3.25M | -10.00M | 12.68M | -2.70M |